HOWL/Ambros công bố sáp nhập và đợt phát hành trị giá 150 triệu USD để tài trợ cho pha 3 của neridronate

Trích đoạn nguồn

EX-99.1 11 d102535dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement • Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-approved therapy • Pivotal CRPS-RISE Phase 3 trial evaluating neridronate remains ongoing, with FDA Breakthrough Therapy, Fast Track and Orphan Drug designations received and alignment with FDA that a single successful pivotal trial could potentially support approval • Neridronate has been administered to approximately 600,000 patients in Ita

SEC 8-K